# Overview of the NURTURE Study
Keywords: SMA, 5q SMA, SPINRAZA, NURTURE study, pre-symptomatic SMA, respiratory intervention, motor milestones, safety outcomes

> This page provides an overview of the NURTURE study, a clinical trial evaluating the efficacy and safety of SPINRAZA in pre-symptomatic infants genetically diagnosed with SMA, including key findings from the final 8-year analysis.

## Details
- [What is NURTURE](#): The NURTURE study is a Phase II, open-label trial assessing SPINRAZA in 25 pre-symptomatic SMA patients under 6 weeks old at the first dose.
- [Key Findings from the 8-Year Analysis](#): 100% of treated patients were alive without permanent ventilation, and 80% never required respiratory intervention.
- [Motor Milestones](#): Most patients achieved motor milestones within normal developmental timeframes, contrasting with the natural history of SMA.
- [Safety Outcomes](#): SPINRAZA was generally well tolerated, with no new safety concerns identified over 8 years of follow-up.
- [Study Design](#): The study included infants most likely to develop SMA Type I or II, with a primary endpoint of time to death or respiratory intervention.